
News|Articles|March 23, 2022
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of March 23, 2022
Author(s)Sydney Jennings
Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.
Advertisement
How many fully vaccinated Americans have received a booster dose?
According to the Centers for Disease Control and Prevention (CDC) as of today, March 23, 2022, at 4:34 PM, EDT:
44.6% of fully vaccinated persons in the US have received a booster dose of COVID-19 vaccine.
What percentage of people across age groups in the US have been fully vaccinated?
According to the CDC as of today, March 23, 2022, at 4:34 PM, EDT:
• 65.4% of total US population
• 69.5% of US population aged ≥5 years
• 73.8% of US population aged ≥12 years
• 75.3% of US population aged ≥18 years
• 88.9% of US population aged ≥65 years
The 5 states/territories with the highest percentage of population fully vaccinated are:
1. Puerto Rico: 82%
2. Rhode Island: 81.4%
3. Vermont: 80.4%
4. Maine: 78.7%
5. Connecticut: 78.3%
2. Rhode Island: 81.4%
3. Vermont: 80.4%
4. Maine: 78.7%
5. Connecticut: 78.3%
How many cases of COVID-19 have been confirmed in the US?
According to the Johns Hopkins COVID-19 interactive map , as of today, March 23, 2022 at 4:20 PM, EDT, there have been:
• 79 825 306 confirmed cases and
• 974 235 deaths
• 974 235 deaths
The 5 states with the highest total confirmed cases are:
1. California: 9 079 544
2. Texas: 6 698 577
3. Florida: 5 868 263
4. New York: 4 967 118
5. Illinois: 3 058 196
2. Texas: 6 698 577
3. Florida: 5 868 263
4. New York: 4 967 118
5. Illinois: 3 058 196
Deaths: California has the highest number of deaths due to COVID-19 with 88 321 reported fatalities, followed by Texas with 86 997 and Florida with 72 828.
How many cases of COVID-19 have been confirmed globally?
Globally, there have been 474 913 330 confirmed cases, 6 102 518 deaths, and 10 835 408 732 vaccine doses administered.
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Advertisement
Advertisement
Trending on Patient Care Online
1
Topline Real-World Data Show Fezolinetant Improves VMS, Sleep, and Work Productivity in Women With Confirmed Menopausal VMS
2
Pooled Safety Analysis Supports Elinzanetant for Vasomotor Symptoms Through 52 Weeks
3
Four Studies Build Evidence for Elinzanetant as a Safe, Effective Nonhormonal Option for Menopausal Vasomotor Symptoms
4
Elinzanetant Improves Sleep Through VMS-Independent Mechanisms, According to New Pooled Analysis
5